Tijerina M, Fowers K D, Kopecková P, Kopecek J
Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City 84112, USA.
Biomaterials. 2000 Nov;21(21):2203-10. doi: 10.1016/s0142-9612(00)00161-7.
The acquisition of multidrug resistance in human ovarian carcinoma A2780 cells was investigated after chronic exposure to free mesochlorin e6 monoethylenediamine (Mce6) and N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound Mce6 (P(GG)-Mce6). The dose that inhibits growth by 50% (IC50) was determined for free Mce6 (2.09 +/- 0.32 microM) and P(GG)-Mce6 (204.15 +/- 28.97 microM) to utilize similar effective doses of drug. A total of 14 drug exposures were performed over a period of 78 days. Cells were characterized by IC50 dose, MDR1 gene expression and anti-human P-glycoprotein (P-gp) antibody binding after each drug exposure. At the conclusion of the experiment, neither the A2780 cells habitually exposed to free Mce6 or P(GG)-Mce6 were significantly different than the control A2780 cells indicating cells did not acquire a MDR phenotype. The doxorubicin (DOX)-resistant A2780/AD cells served as a positive control.
在人卵巢癌A2780细胞长期暴露于游离的中氯e6单乙二胺(Mce6)和N -(2 - 羟丙基)甲基丙烯酰胺(HPMA)共聚物结合的Mce6(P(GG)-Mce6)后,研究了其多药耐药性的获得情况。测定了游离Mce6(2.09±0.32微摩尔)和P(GG)-Mce6(204.15±28.97微摩尔)抑制生长50%的剂量(IC50),以使用相似的有效药物剂量。在78天的时间内共进行了14次药物暴露。每次药物暴露后,通过IC50剂量、MDR1基因表达和抗人P - 糖蛋白(P - gp)抗体结合对细胞进行表征。在实验结束时,习惯性暴露于游离Mce6或P(GG)-Mce6的A2780细胞与对照A2780细胞相比均无显著差异,表明细胞未获得多药耐药表型。阿霉素(DOX)耐药的A2780/AD细胞用作阳性对照。